Navigation Links
Phase 3 Data Show Intravenous Golimumab Inhibited Radiographic Progression in Patients with Active Rheumatoid Arthritis
Date:11/12/2012

om placebo to I.V. golimumab during the trial (P < 0.001).  Patients randomized to I.V. golimumab and those in the crossover group had a mean change in total vdH-S score of 0.15 (+/- 1.83) and 0.12 (+/- 2.44), respectively, from week 24 to 52, supporting inhibition of structural damage progression in all patients receiving I.V. golimumab.

Significant proportions of patients receiving I.V. golimumab also demonstrated improvements in signs and symptoms compared with patients receiving placebo according to ACR scores, European League Against Rheumatism (EULAR)/Disease Activity Score (DAS) 28 C-reactive protein (CRP) response criteria and Health Assessment Questionnaire (HAQ) disability scores at weeks 14 and 24.  A majority of those patients who achieved ACR 20, ACR 50, ACR 70 and EULAR/DAS 28 CRP good/moderate response by week 24 maintained response through week 52 (82 percent of ACR20 responders; 71.7 percent of ACR 50 responders; 60.9 percent of ACR 70 responders; 80 percent demonstrating DAS28-CRP good/moderate response).  The EULAR/DAS 28 CRP is a measure of disease activity in patients with RA that is calculated by assessing the number of tender and swollen joints (among a total of 28), serum CRP level (indicator of inflammation), and the patient's assessment of global health. 

Through week 52 of the GO-FURTHER trial, the safety profile of I.V. golimumab remained consistent with previously reported week 24 data.  Through week 24, adverse events (AEs) occurred in 53 percent of patients receiving I.V. golimumab and 49 percent of patients receiving placebo, and serious AEs were reported in more I.V. golimumab-treated patients (4 percent) than placebo-treated patients (2 percent).  Rates of AEs and serious AEs at week 52 among patients receiving I.V. golimumab were 65 percent and 9 percent, respectively.  There were no serious opportunistic infections through week 52 of the study.  One case of tubercul
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets  has ... Pipeline Insight 2014" report to their offering. ... is one of the largest segments of pharmaceuticals industry. The ... while the available therapies were unable to meet the market ... market for CNS disorder, especially over the past two decades. ...
(Date:8/29/2014)... SILVER SPRING, Md. , Aug. 29, 2014 /PRNewswire/ ... today that the U.S. District Court for the District ... in its favor in the company,s case against Sandoz, ... opinion, Judge Peter Sheridan ruled that U.S. ... Sandoz, Inc., and enjoined Sandoz from marketing its generic ...
(Date:8/29/2014)... Pa. , Aug. 29, 2014  Unilife Corporation ... UNS) announced today that it intends to release its ... year ended June 30, 2014 after market trading ends ... has scheduled a conference call for 4:30 p.m. U.S. ... 2014 at 6:30 a.m. AEST), to review the Company,s financial ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2
... Biosciences announced,today, the initiation of a Phase 2 ... management of acute infectious,mononucleosis. Currently, there are no ... or any other disease caused by,the Epstein-Barr virus ... of anti-viral activity,including inhibition of viral replication of ...
... Dec. 6 Rigel,Pharmaceuticals, Inc. (Nasdaq: RIGL ) ... ), has begun a Phase 1 clinical trial of ... R343,for the treatment of allergic asthma. R343 is the ... terms of the companies, 2005 collaboration agreement, Rigel,will receive ...
Cached Medicine Technology:Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis 2Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer 2Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer 3
(Date:8/30/2014)... (PRWEB) August 30, 2014 Final ... release of the TransGhost plugin from Pixel Film Studios. ... gives users the ability to tell their scary story ... Pixel Film Studios. “Users will make their audience scream ... plugin.” , With TransGhost users can awaken evil spirits ...
(Date:8/30/2014)... 30, 2014 Zensah®, the leader in compression ... Leg Sleeve . The camo sleeves are the first released ... collection. The camo line includes classic colors like army green ... , Known as tibial stress syndrome, shin splints cause dull ... leg. Swollen and irritated muscles, stress fractures, or over pronation ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 Barton Associates, ... practitioner locum tenens company , announces a new ... 1, 2014. Barton Associates is headquartered in Peabody, MA, ... Keene, NH; and Jupiter, FL. , Barton ... the increasing demand for healthcare providers. The United States ...
(Date:8/30/2014)... The KSF (Kung Fu Sanshou Federation) ... on November 8th, 2014 at the Mobile Civic Center ... introduced many notorious and notable fighters for some top ... UFC. , Among these KSF along with the ... armed with the virtues of true indomitable Shaolin spirit, ...
(Date:8/30/2014)... What challenges exist in recruiting top talent for ... and considerations? Sports Conflict Institute ’s Joshua ... Woody Wommack, Southeast Football Recruiting Analyst of Rivals.com/Yahoo! Sports ... Notably, Wommack spoke on what the recruiting process ... are coming as a result of the O’Bannon trial, ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Released TransGhost Plugin for Final Cut Pro X Today 2Health News:Pixel Film Studios Released TransGhost Plugin for Final Cut Pro X Today 3Health News:Camo Compression Leg Sleeves Provide Shin Splint Relief for Runners 2Health News:Barton Associates Announces New Office Location in Austin, TX 2Health News:KSF Presents US Open Challenge-K. Warrior Search, Seeking Inspirational Warrior Fighters Like Cung Le 2Health News:KSF Presents US Open Challenge-K. Warrior Search, Seeking Inspirational Warrior Fighters Like Cung Le 3Health News:KSF Presents US Open Challenge-K. Warrior Search, Seeking Inspirational Warrior Fighters Like Cung Le 4Health News:Woody Wommack of Rivals.com Discusses the World of NCAA Football Recruiting on SCI TV 2Health News:Woody Wommack of Rivals.com Discusses the World of NCAA Football Recruiting on SCI TV 3
... ... TUMSRacing.com, PITTSBURGH, July 9 TUMS, one ... nationwide search for,one lucky fan to serve as the Grand Marshal of ... Va. on October,19, 2008., (Photo: http://www.newscom.com/cgi-bin/prnh/20080709/AQW525 ), "TUMS, and ...
... CCA Industries,Inc. (Amex: CAW ) announced today the ... weight loss and cholesterol lowering dietary supplement,to be available ... non drug dietary supplement, formulated with,green tea and a ... be targeted to the approximately 23 million overweight,adults in ...
... researcher Dr. Daniel Von Hoff, a member ... provides an in-depth look at "The Complete ... that creates rapid accrual rates, substantial economies ... investigators and patients, and improved therapeutic benefits. ...
... Health meets global needs for the increasingly complex healthcare ... ... Cohn & Wolfe has announced the,formation of GCI Health, a ... healthcare industry. GCI Health, which,will be led by Jill Dosik as ...
... July 9 The HealthCentral,Network, Inc. ... medical and peer-to-peer resource,committed to helping and ... and nutrition, along with offering a place ... writers, University of Pennsylvania clinical instruction,Dr. Jeffrey ...
... is part of uKarma,s vertical integration strategy and ... launch complementary health and wellness brands, LOS ... UKMA), a lifestyle multimedia and consumer products company,focused ... the,first Xflowsion studio will open in Southern California ...
Cached Medicine News:Health News:TUMS Announces Nationwide Search for Grand Marshal at TUMS QuikPak 500 2Health News:CCA Industries, Inc. Introduces a New Diet Aid Supplement 2Health News:Dr. Daniel Von Hoff Discusses "The Complete Phase Ib," A Clinical Trial Design Offering Faster Drug Development, Economies of Scale and Improved Therapeutic Benefit 2Health News:Dr. Daniel Von Hoff Discusses "The Complete Phase Ib," A Clinical Trial Design Offering Faster Drug Development, Economies of Scale and Improved Therapeutic Benefit 3Health News:Cohn & Wolfe Launches GCI Health, One of the World's Largest Healthcare Public Relations Firms 2Health News:Responding to Increased Incidence of Obesity and Associated Health Issues, The HealthCentral Network Launches Site to Support those Struggling with Weight 2Health News:uKarma to Open First Xflowsion Fitness Studio With Celebrity Trainer Eric Paskel 2
Portal accessory instrument set. Set also includes a package of 8 mm Guide Wires (.15 cm x 38 cm), and Sterilization Tray....
The Small Oval Cannula System is designed to be the smallest oval cannula system currently available, and is utilized with the Caspari Suture Punch System. Disposable seals are available with this sy...
...
Suture retriever forceps...
Medicine Products: